Atricure, Inc.
A maker of surgical tools for treating atrial fibrillation, an irregular heartbeat, this Ohio company's devices include the AtriClip, a clamp that seals a small heart pouch to cut stroke risk, plus ablation systems and cryo probes that numb nerves to ease post-surgery pain. Founded in 2000 by engineer Michael Hooven, the company grew out of his drive to fill a gap in treating serious heart-rhythm problems. Its name blends "atria"—the heart's upper chambers where the condition starts—with "cure."
10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗
AtriCure posted its first meaningful quarter of operating profitability. rose 12.8% to $153.6 million and reached 77.2%, driving to $9.7 million as pain management sales continued to climb and R&D costs moderated. The company is now generating consistent profits and cash flow, with the $260 million SentreHEART lawsuit remaining the primary unresolved risk.
AtriCure is defending a lawsuit seeking up to $260M over alleged failure to use commercially reasonable efforts to obtain FDA approval for the LARIAT System.
In addition to the other information set forth in this report, careful consideration should be given to the factors discussed in Item 1A, “Risk Factors” in our Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition or futu…
In addition to the other information set forth in this report, careful consideration should be given to the factors discussed in Item 1A, “Risk Factors” in our Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition or future results. The risks described therein are not the only risks facing us. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, also may adversely affect our business, financial condition and/or operating results. There have been no material changes with respect to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, which are incorporated herein by reference.
Read original filing text →